Celldex Therapeutics Inc (CLDX) — Institutional Investor Activity (Q2 2026)

CLDX ranks #2410 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

CLDX is a top-conviction position for Kynam Capital Management, LP — at 10.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in CLDX belongs to Wellington Management Group LLP, but the position matters far more to Kynam Capital Management, LP, who has 10.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

GAMMA Investing LLC has added to its CLDX position for two straight quarters, increasing it by $13.8K to reach $22.6K today.

GHP Investment Advisors, Inc. has trimmed its CLDX position for two straight quarters, cutting it by $695.0 while still holding $98.0.

CLDX is down 4.8% today, but institutions show net buying of $648.4M this quarter — a divergence between today's price move and the underlying institutional flow.

CLDX reported a net loss of $300.5M over the trailing twelve months.

• Not yet profitable — net loss of $300.5M over the trailing twelve months
• Revenue declined 97.3% year over year
• Net income declined year over year, from -$199.6M to -$300.5M
• Operating cash flow was negative, using $210.9M in cash
• Current ratio of 10.49x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.11x equity — within a conventional range